1. Home
  2. BUUU vs GLSI Comparison

BUUU vs GLSI Comparison

Compare BUUU & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BUUU

BUUU Group Limited Class A Ordinary Share

N/A

Current Price

$8.39

Market Cap

130.1M

ML Signal

N/A

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$20.41

Market Cap

123.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BUUU
GLSI
Founded
2017
2006
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
130.1M
123.9M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
BUUU
GLSI
Price
$8.39
$20.41
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$39.00
AVG Volume (30 Days)
9.7K
432.5K
Earning Date
01-06-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$6,328,425.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$158.62
N/A
Revenue Growth
8.88
N/A
52 Week Low
$3.67
$7.78
52 Week High
$9.50
$22.31

Technical Indicators

Market Signals
Indicator
BUUU
GLSI
Relative Strength Index (RSI) N/A 91.37
Support Level N/A $13.11
Resistance Level N/A $13.76
Average True Range (ATR) 0.00 1.88
MACD 0.00 1.00
Stochastic Oscillator 0.00 90.54

Price Performance

Historical Comparison
BUUU
GLSI

About BUUU BUUU Group Limited Class A Ordinary Share

BUUU Group Ltd provides comprehensive meetings, incentives, conferences, and exhibitions (MICE) solutions focused on event management and stage production. Its event management team offers creative planning, project management, and on-site supervision for a wide range of cultural, artistic, recreational, and corporate events, working closely with clients and partners. The stage production team creates immersive event experiences by managing lighting, audio-visual systems, stage performance elements, and venue decorations, overseeing the entire production process. Event management generates the majority of revenue.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: